MedTrace Logo

Risk of Nerve Damage After Administration of Local Anesthesia

NCT06564987 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-26

No results posted yet for this study

Summary

This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.

Conditions

  • Inferior Alveolar Nerve Injuries

Interventions

DRUG

4% Articaine with 1:200,000 epinephrine

Inferior Alveolar Nerve Block with 4% articaine

DRUG

2% lidocaine with 1:100,000 epinephrine

Inferior Alveolar Nerve Block with 2% lidocaine

Sponsors & Collaborators

  • Cleveland Dental Institute

    lead OTHER

Principal Investigators

  • Ahmed A Hashem, PhD · Cleveland Dental Institute

  • Waleed Elmallah, PhD · Cleveland Dental Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-12-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06564987 on ClinicalTrials.gov